Lixte Biotechnology (LIXT) - Quarterly EPS earnings growth

Official company branding of Lixte Biotechnology Holdings, Inc. (LIXT)

Lixte Biotechnology is scaling combined cancer treatment methods through collaborations with global oncology centers. The company's scientific potential relies on the development of LB-100 inhibitors to enhance chemotherapy. This GURU.Markets chart of quarterly net earnings per share growth reflects a trend where the value of 37.40 characterizes this level. However, the absence of sales and uncertainty regarding clinical outcomes render the asset speculative.

Lixte Biotechnology Holdings, Inc. (LIXT) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 07/06/2026

Analytical breakdowns for Lixte Biotechnology

- market value and analyst target forecast:
Price Chart Lixte Biotechnology Holdings, Inc.|LIXT - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Lixte Biotechnology Holdings|LIXT - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Lixte Biotechnology|LIXT - Total Stockholders' Equity|Market Value to Book Value Ratio lixte.com|LIXT - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Lixte Biotechnology|LIXT - Long-Term Liabilities to Capital|Short-Term Debt to Capital Lixte Biotechnology|LIXT - Company Total Indebtedness|Debt to Book Value Lixte Biotechnology Holdings|LIXT - Long-Term Debt|Company Current Liabilities Lixte Biotechnology|Quick Liquidity Indicator lixte.com
- earnings and market multiples details:
LIXT - Profit After Payment of Taxes|Projected Future Earnings Lixte Biotechnology|LIXT - Company Value to Net Income|Forward P/E Multiple Lixte Biotechnology Holdings|LIXT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lixte Biotechnology Holdings|LIXT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Lixte Biotechnology|LIXT - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months lixte.com|LIXT - Earnings per share trend in current year|Expected earnings per share growth for next year Lixte Biotechnology
Fundamental company analysis:Lixte Biotechnology Holdings, Inc., LIXT
Manufactured product of Lixte Biotechnology, Inc.

Investors are assessing the resilience of Lixte Biotechnology (LIXT) through the growth rate of earnings per share, which measures the real pace of business capitalization compared to the previous quarter. Analyzing the quarterly EPS dynamics allows for linking financial momentum to the efficiency of small molecule synthesis capacity upgrades, confirming the company's ability to ensure continuity of drug supplies.

Analysis of competing companies

Incyte (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months HCM|NUVB (Nuvation Pharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Day One Biopharmaceuticals Inc (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Therapeutics (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Biopharma IMAB|Fennec Pharma - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year corbuspharma.com CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring, Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla, Inc.)|CTXR (citiuspharma.com) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (biolinerx.com)|Can-Fite BioPharma Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (Aprea Therapeutics)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion Therapeutics (SLXN)|Year-over-year earnings per share growth for the last twelve months NuCana PLC|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth g1therapeutics.com (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Pharma) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months portagebiotech.com